Industry: In the next five years, the pharmaceutical industry has three investment opportunities

Since 2020, the pharmaceutical industry has undoubtedly received a high degree of attention since 2020, according to theof Market Analysis of thePharmaceutical NetworkIn the medium to long term, medicine is just in demand, the future demand certainty is relatively high, and benefit from the aging of the population, consumption level upgrading, policy and other factors, the development prospects of the pharmaceutical industry is generally optimisticDue to the many segments of the pharmaceutical industry, industry analysts believe that in the next five years, the pharmaceutical industry has three main investment opportunitiesDomestic replacement of medical devicesfor example, such as from the in vitro diagnostic chemical luminous methodology, now in the tertiary hospital medical equipment is still by Roche, Abbott, Siemens, Beckman and other imported devices occupy the main market share, Japan Olympus, Pentax, Fuji three basic monopoly of the domestic endoscope, digestive endoscopy industryin these sub-sectors, there is a real gap in domestic technology in the past, but in recent years, with china's people's living standards improving, aging of the population, medical demand is increasing, China's medical device market demand continues to expandAt the same time, a series of favorable policy support and a good environment, to promote the expansion of the medical device marketunder the dual pull of policy and market, the size of China's medical device market has been increasing year by yearData show that in 2018, China's medical device market size of 301.3 billion yuan, up 20% YoY, is expected to maintain relatively stable growth in 2019, the market size of nearly 355.5 billion yuanindustry analysts believe that with the continuous progress of domestic technology, as well as the accumulation of research and development, the future is expected to achieve domestic substitution in these sub-sectorsCDMO industry andAPIindustrysome global industries such as CDMO industry and API industry, with the reduction of domestic costs and progress of the process, is showing a trend of domestic transfer In recent years, under pressure from the rapidly rising cost of new drug research and development and health-care costs, more and more pharmaceutical companies are focusing their business on more core drug development through strategic divestitures Many of the world's largest pharmaceutical companies are spun off and outsourced their small-molecule drug development and production departments, focusing more on the development of macromolecule drugs This has been in the small molecule drug technology development, production field has accumulated a lot of technical advantages of domestic CDMO enterprises to bring development opportunities The industry believes that in the future, with multinational pharmaceutical companies research and development centers have to China to "set up camp", China's pharmaceutical research and development industry chain is becoming more and more mature, the domestic CRO market size will continue to expand while demand in the API industry is relatively stable, and overseas production capacity may also be transferred to the domestic market Forecasts show that by 2020, the global API market will increase to 186.4 billion U.S dollars, a growth rate of more than 6%, China as a major producer of API, the market size will further expand In the medium to long term, quality and cost advantageremain remain key Innovative drug circuit innovative drug has been called by the industry as "the investment gold mine in the eyes of investment institutions for the next decade" China's innovative drug market has huge space, with the introduction and promotion of policies such as "two-vote system", "belt procurement", "priority review and approval system", "quality and efficacy evaluation of generic drugs" and so on, encouraging the upgrading of pharmaceutical industry, increasing enthusiasm for innovative research and development of pharmaceutical companies, coupled with the strong demand brought about by the growing domestic drug market and aging, it is expected that the future may bring hundreds to trillions of levels of incremental market.